Cytotoxicity and reactive oxygen species generated by ferrocenium and ferrocene on MCF7 and MCF10A cell lines

Journal of Cancer Science and Therapy

Volumn 4, Issue 9, 2012, Pages 271-275

  Acevedo Morantes, Claudia Y ^a   Meléndez, Enrique ^a   Singh, Surinder P ^a   Ramírez Vick, Jaime E ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Ferrocene; Ferrocenium; MCF10A cells; MCF7 cells; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENT; FERROCENE; FERRROCENIUM; ORGANOMETALLIC COMPOUND; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 10A; CELL STRAIN MCF 7; CELL TYPE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFECT; EPITHELIUM CELL; HUMAN; HUMAN TISSUE;

EID: 84867503733     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000154     Document Type: Article

References (23)

1. Kealy TJ, Pauson PJ (1951) A New Type of Organ-Iron Compound. Nature 168: 1039-1040.
2. Miller SA, Tebboth JA, Treamaine JF (1952) Dicyclopentadienyliron. J Am Chem Soc 632-635.
3. Togni A, Hayashi T (1995) Ferrocenes: Homogenoeous catalysis, organic synthesis, material science. VCH, Weinheim, Germany.
4. Gómez Arrayás R, Adrio J, Carretero JC (2006) Recent applications of chiral ferrocene ligands in asymmetric catalysis. Angew Chem Int Ed Engl 45: 7674-7715.
5. Togni A, Halterman RL (1998), Metallocenes. Wiley-VCH, Weinheim, Germany.
6. Atkinson RC, Gibson VC, Long NJ (2004) The syntheses and catalytic applications of unsymmetrical ferrocene ligands. Chem Soc Rev 33: 313-328.
7. Köpf-Maier P, Köpf H, Neuse EW (1984) Ferricenium complexes: a new type of water-soluble antitumor agent. J Cancer Res Clin Oncol 108: 336-340.
8. Tabbi G, Cassino C, Cavigiolio G, Colangelo D, Ghiglia A, et al. (2002) Water stability and cytotoxic activity relationship of a series of ferrocenium derivatives. ESR insights on the radical production during the degradation process. J Med Chem 45: 5786-5796.
9. Osella D, Mahboobi H, Colangelo D, Cavigiolio G, Vessieres A, et al. (2005) FACS analysis of oxidative stress induced on tumor cells by SERMs. Inorg Chim Acta 358: 1993-1998.
10. Kovjazin R, Eldar T, Patya M, Vanichkin A, Lander HM, et al. (2003) Ferrocene induced lymphocyte activation and anti-tumor activity is mediated by redox sensitive signaling. FASEB J 17: 467-469.
11. Top S, Vessières A, Leclercq G, Quivy J, Tang J, et al. (2003) Synthesis, Biochemical Properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. Chemistry 9: 5223-5236.
12. Ming-Gao L, Hernández R, Matta J, Meléndez E (2009) Synthesis, structure, electrochemistry and cytotoxic properties of ferrocenyl ester derivatives. Met Based Drugs 2009: 420784.
13. Wang T, Wan P, Ma L (2006) Synthesis and Characterization of Alkoxy and Phenoxy-substituted Ferrocenium Salt Cationic Photoinitiators. Chinese J Chem Eng 14: 806-809.
14. Hanley C, Layne J, Punnoose A, Reddy KM, Coombs I, et al. (2008) Preferential killing of cancer cells and activated human T cell using ZnO nanoparticles. Nanotechnology 19: 295103.
15. Zhang Y, Yang M, Park JH, Singelyn J, Ma H, et al. (2009) A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles. Small 5: 1990-1996.
16. Lovrić J, Cho SJ, Winnik FM, Maysinger D (2005) Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol 12: 1227-1234.
17. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591.
18. Jaouen G (2006) Bioorganometallics. Wiley-VCH, Weinheim, Germany.
19. Hillard EA, Vessières A, Jaouen G (2010) Ferrocene Functionalized Modulators as Anticancer Agents. Top Organomet Chem 32: 81-117.
20. van Staveren DR, Metzler-Nolte N (2004) Bioorganometallic chemistry of ferrocene. Chem Rev 104: 5931-5985.
21. Fouda MFR, Abd-Elzaher MM, Abdelsamaia RA, Labib AA (2007) On the medicinal chemistry of ferrocene. App Organometal Chem 21: 613-625.
22. Gasser G, Ott I, Metzler-Nolte N (2011) Organometallic Anticancer Compounds. J Med Chem 54: 3-25.
23. Vera J, Gao LM, Santana A, Matta J, Meléndez E (2011) Vectorized ferrocenes with estrogens and vitamin D2: synthesis, cytotoxic activity and docking studies. Dalton Trans 40: 9557-9565.